Kansas PKD Research and Translation Core Center - Administrative Core

堪萨斯 PKD 研究和翻译核心中心 - 行政核心

基本信息

批准号：
10686055
负责人：
JAMES P CALVET
金额：
$ 10.57万
依托单位：
UNIVERSITY OF KANSAS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-15 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10686055
关键词：
Abnormal Cell Advisory Committees Advocate Area Autosomal Dominant Polycystic Kidney Biochemistry Biocompatible Materials Biological Markers Biomedical Research Cancer Center Cell Proliferation Cell model Cellular biology Clinical Investigator Clinical Research Clinical Trials Collaborations Communication Communities Cyst Decision Making Development Disease Disease Progression Education Educational workshop Effectiveness Ensure Evaluation FDA approved Fluids and Secretions Funding Genetic Models Grant Growth Institution Kansas Malignant Neoplasms Mission National Institute of Diabetes and Digestive and Kidney Diseases Pathway interactions Patient-Focused Outcomes Patients Play Reagent Recording of previous events Research Research Methodology Research Personnel Research Project Grants Research Support Resource Sharing Resources Review Committee Rodent Model Role Scientist Services Signal Transduction Site Techniques Technology Testing Translational Research Translations Work biomarker discovery clinical development clinical translation drug testing falls improved innovation member novel patient oriented programs recruit summer student symposium therapeutic target tolvaptan

项目摘要

Project Summary - Administrative Core The mission of the Kansas PKD Research and Translation Core Center (RTCC) is to promote PKD research by providing essential reagents, biomaterials, and service to the PKD research community for the advancement of our understanding of disease mechanisms, the discovery of biomarkers and therapeutic targets and the development of clinical trials to improve patient outcomes. The mission of the Center is based on research at Kansas that discovered and characterized many of the key pathways now being considered for PKD therapy, and that ultimately led to the development of Tolvaptan as the first FDA approved therapy for ADPKD. The Kansas PKD RTCC has created three biomedical research cores to support the research programs of external core users in the PKD Research Consortium and the greater PKD research community. These cores are: Core 1. Biomarkers, Biomaterials, and Cellular Models (Darren Wallace, Director), Core 2. Rodent Models & Drug Testing (Pamela Tran and Stephen Parnell, Co-Directors), and Core 3. Clinical Research (Alan Yu, Director). The Administrative Core will be responsible for setting the overall scientific direction of the Kansas PKD Center, overseeing core activities, and for prioritizing the distribution of resources to each of the cores. The Administrative Core will also be responsible for organizing a variety of educational enrichment activities, including a Summer Student Enrichment Program, PKD research methods workshops, professional development sessions, Research Methods and Advanced Technologies Program, research seminars, retreats, patient- oriented activities, and will work with the Central Coordinating Site (CCS) on the annual symposium. The Administrative Core has an Internal Advisory Committee (IAC) comprised of the center directors and core directors and established KUMC scientists outside the PKD field who will bring their expertise to the committee, plus a representative from the PKD patient community to serve as a patient advocate. All PKD Core Center activities will be regularly reviewed and evaluated by the Internal Advisory Committee for communication to the CCS Steering Committee, the External Evaluation Panel (EEP), and NIDDK. The Administrative Core will support the recruitment of new investigators into the PKD field through various mechanisms including an innovative internal pilot grant program in partnership with the KU Cancer Center to support research projects exploring the relationship between PKD and cancer. Finally, the Administrative Core will work to promote strong interactions between the Kansas PKD Center and the institution by interfacing its activities with other programs, centers, and institutes at KUMC, and by integrating the biomedical research cores with existing institutional shared resource centers and biomedical cores; and will encourage open and frequent communication with the CCS and with the other national PKD RTCCs to maximize the benefits offered by our unique, high-value core services to the national PKD community.

项目摘要 - 行政核心堪萨斯州PKD研究与翻译核心中心（RTCC）的任务是促进PKD 通过为PKD研究社区提供基本试剂，生物材料和服务来进行研究促进我们对疾病机制的理解，生物标志物的发现和治疗靶标以及开发临床试验以改善患者预后。该中心的任务是基于堪萨斯州的研究发现并表征了PKD的许多关键途径疗法，这最终导致了Tolvaptan的发展，这是FDA批准的ADPKD疗法。堪萨斯州PKD RTCC创建了三个生物医学研究核心，以支持 PKD研究联盟和大PKD研究社区的外部核心用户。这些核心为：核心1。生物标志物，生物材料和蜂窝模型（Darren Wallace，董事），核心2。啮齿动物模型＆药物测试（Pamela Tran和Stephen Parnell，联合指导）和Core 3。临床研究（Alan Yu，导演）。行政核心将负责设定堪萨斯州的整体科学方向 PKD中心，监督核心活动，并优先考虑向每个核心的资源分配。这行政核心还将负责组织各种教育丰富活动，包括夏季学生丰富计划，PKD研究方法研讨会，专业发展会议，研究方法和高级技术计划，研究研讨会，务虚会，患者 - 定向活动，并将在年度研讨会上与中央协调站点（CCS）合作。这行政核心有一个由中心董事和核心组成的内部咨询委员会（IAC） PKD领域以外的董事和建立了KUMC科学家，他们将把专业知识带给委员会，加上PKD患者社区的代表，担任患者倡导者。所有PKD核心中心活动将由内部咨询委员会定期审查和评估与该活动 CCS指导委员会，外部评估小组（EEP）和NIDDK。行政核心将支持通过包括创新的各种机制招募新的研究人员进入PKD领域内部试点赠款计划与KU癌症中心合作，以支持研究项目 PKD与癌症之间的关系。最后，行政核心将努力促进强烈的互动在堪萨斯州PKD中心与机构之间的活动与其他计划，中心和 KUMC的机构，并通过将生物医学研究核心与现有机构共享资源相结合中心和生物医学核心；并会鼓励与CCS以及与CCS的公开沟通其他国家PKD RTCCS最大化我们独特的高价值核心服务提供的利益国家PKD社区。